Nebivolol

Generic Name: Nebivolol

Brand Names: Bystolic

Nebivolol is a newer generation beta-blocker with vasodilating properties, used to treat high blood pressure.

CardiovascularBeta Blocker

Drug Class

Third-Generation Cardioselective Beta-1 Blocker with Nitric Oxide-Mediated Vasodilation

Pregnancy

Category C — Animal reproduction studies have shown adverse effects at high doses; no adequate human studies. Beta blockers used near term may cause neonatal bradycardia, hypoglycemia, and respiratory depression. Use during pregnancy only if the potential benefit justifies the potential risk; labetalol is generally preferred when a beta blocker is needed in pregnancy.

Available Forms

Oral tablet (2.5 mg, 5 mg, 10 mg, 20 mg)

What It's Used For

Hypertension treatment
Blood pressure control in patients with diabetes or metabolic syndrome
Alternative beta-blocker for patients concerned about erectile dysfunction
Patients requiring beta-blocker with favorable metabolic profile

Dosage Quick Reference

These are general dosage guidelines. Your doctor will determine the appropriate dose for your specific situation.

Condition	Starting Dose	Maintenance Dose
Hypertension (most adults)	5 mg once daily	Titrate at 2-week intervals to 10–40 mg once daily; max 40 mg/day
Hypertension — moderate hepatic impairment	2.5 mg once daily	Titrate cautiously; max 10 mg/day
Hypertension — severe renal impairment (CrCl < 30 mL/min)	2.5 mg once daily	Titrate cautiously based on response
Heart failure (off-label, European data)	1.25 mg once daily	Double dose every 1–2 weeks as tolerated to target 10 mg once daily

Side Effects

Common Side Effects:

Headache
Fatigue
Dizziness
Diarrhea
Nausea
Insomnia
Peripheral edema

Serious Side Effects (seek immediate medical attention):

Severe bradycardia (very slow heartbeat)
Signs of heart failure (shortness of breath, swelling, weight gain)
Severe hypotension (dizziness, fainting)
Bronchospasm (wheezing, difficulty breathing)
Signs of allergic reaction (rash, itching, swelling)

Drug Interactions

Nebivolol is metabolized primarily by CYP2D6, and as a beta blocker it shares pharmacodynamic interactions common to the class.

Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion, quinidine): Substantially increase nebivolol exposure, potentially intensifying bradycardia and hypotension. Use the lowest effective nebivolol dose and monitor heart rate and blood pressure.
Other negative chronotropes (verapamil, diltiazem, digoxin, amiodarone, ivabradine): Additive risk of bradycardia, AV block, and hypotension. Avoid combining nebivolol with non-dihydropyridine calcium channel blockers in patients with conduction disease.
Clonidine: Abrupt discontinuation of clonidine while a beta blocker is on board can produce severe rebound hypertension. When stopping clonidine, taper the beta blocker first or stop both gradually.
Insulin and oral antidiabetic agents: Beta blockers can blunt the adrenergic warning signs of hypoglycemia (tremor, tachycardia) while leaving sweating intact. Counsel diabetic patients to monitor glucose more closely after dose changes.
Inhaled bronchodilators / asthma medications: Although nebivolol is highly beta-1 selective at low doses, selectivity diminishes at higher doses. Use cautiously in patients with severe asthma or brittle COPD.
NSAIDs: May blunt the antihypertensive effect of beta blockers. Use the lowest effective NSAID dose for the shortest duration.

Additional Information

Nebivolol is a third-generation, highly selective beta-1 adrenergic receptor blocker with unique vasodilating properties mediated through nitric oxide. This combination of cardioselective beta-blockade and nitric oxide-mediated vasodilation makes it particularly useful for hypertension treatment, with a favorable metabolic and tolerability profile compared to older beta-blockers.

Mechanism of Action

Nebivolol works through two distinct mechanisms that together provide effective blood pressure control with excellent tolerability. First, it blocks beta-1 adrenergic receptors in the heart with exceptional selectivity (approximately 320-fold greater affinity for beta-1 than beta-2 receptors), reducing heart rate and cardiac output. Second, it stimulates endothelial nitric oxide synthase, promoting nitric oxide release and causing vasodilation. This vasodilating property is unique among beta-blockers and contributes to blood pressure lowering without the peripheral vasoconstriction seen with traditional beta-blockers.

The nitric oxide pathway also provides potential benefits including improved endothelial function, reduced oxidative stress, and favorable effects on insulin sensitivity. These properties may make nebivolol particularly suitable for patients with diabetes, metabolic syndrome, or erectile dysfunction who require beta-blocker therapy.

Available Formulations

Nebivolol (Bystolic) is available as tablets in multiple strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg. The tablets are scored for flexible dosing. Generic versions are now available, making this medication more accessible for patients requiring long-term therapy.

FDA-Approved Indications

Nebivolol is FDA-approved for the treatment of hypertension in adults. It may be used alone or in combination with other antihypertensive agents. While not FDA-approved for heart failure in the United States, clinical trial evidence (SENIORS trial) supports its use in elderly patients with heart failure, and it is approved for this indication in some other countries.

Dosing Guidelines

The recommended starting dose for hypertension is 5 mg once daily. The dose may be increased at 2-week intervals up to a maximum of 40 mg once daily as needed for blood pressure control. For patients with moderate hepatic impairment or severe renal impairment (CrCl less than 30 mL/min), the recommended starting dose is 2.5 mg once daily, with careful upward titration as needed. The medication can be taken with or without food and should be administered at approximately the same time each day.

Cardioselectivity and Metabolic Advantages

The high beta-1 selectivity of nebivolol provides several clinical advantages compared to non-selective beta-blockers. It is less likely to cause bronchospasm and may be used more safely in patients with mild asthma or COPD, although caution is still warranted. Unlike older beta-blockers, nebivolol does not significantly impair glucose metabolism or worsen lipid profiles. Clinical studies have shown neutral to favorable effects on insulin sensitivity, making it a preferred choice when beta-blocker therapy is needed in patients with diabetes or metabolic syndrome.

Important Safety Considerations

Nebivolol should not be discontinued abruptly, as this may exacerbate angina or precipitate myocardial infarction. Dose should be gradually reduced over 1-2 weeks when discontinuing. The medication is contraindicated in severe bradycardia, heart block greater than first degree (without pacemaker), cardiogenic shock, decompensated heart failure, and severe hepatic impairment. While more cardioselective than older agents, caution is still advised in patients with bronchospastic disease.

Drug Interactions

CYP2D6 inhibitors such as fluoxetine, paroxetine, and quinidine can significantly increase nebivolol levels and should be used with caution. Beta-blockers can mask hypoglycemia symptoms in diabetic patients. Additive bradycardia may occur with digoxin, diltiazem, or verapamil. Catecholamine-depleting drugs like reserpine may have additive effects. Sildenafil and other PDE5 inhibitors may enhance hypotensive effects.

Special Populations

In patients who are CYP2D6 poor metabolizers (approximately 10% of Caucasians), nebivolol exposure is increased, potentially requiring lower doses. Elderly patients may require lower initial doses and careful titration. Use during pregnancy should be avoided if possible, as beta-blockers may cause fetal bradycardia. Safety in pediatric patients has not been established.

Learn more at MedlinePlus

Frequently Asked Questions

Nebivolol is highly selective for the beta-1 receptor and uniquely stimulates endothelial nitric oxide release, producing vasodilation in addition to slowing the heart. This combination tends to lower blood pressure with less fatigue, less impact on cholesterol and glucose, and a lower reported rate of erectile dysfunction compared with older non-selective agents.

A measurable drop in blood pressure usually occurs within 1 to 2 weeks of starting therapy, with the maximal effect reached over 4 to 6 weeks. Your physician will typically reassess at that interval before titrating the dose. Home blood pressure monitoring helps guide adjustments more quickly than office readings alone.

Yes, in most cases. Beta blockers blunt the heart rate response to exertion, so target heart rate goals based on age may not apply. Use perceived exertion or talk-test guidelines instead. If you feel unusual shortness of breath, dizziness, or chest discomfort during exercise, stop and contact your physician.

Take the missed dose as soon as you remember if it is within several hours of the scheduled time. If it is closer to your next dose, skip the missed one and resume your usual schedule. Do not double up. Setting a daily reminder helps because consistent dosing produces the steadiest blood pressure control.

No. Abrupt discontinuation of any beta blocker can trigger rebound hypertension, angina, or in rare cases a heart attack — particularly in patients with coronary artery disease. If you must stop, taper over at least 1 to 2 weeks under medical guidance. Plan refills in advance to avoid gaps.

Questions to Ask Your Doctor

Consider discussing these topics at your next appointment:

✓Is nebivolol the right beta blocker for me, or might another agent fit my situation better?
✓What home blood pressure and heart rate readings should prompt me to call your office?
✓Could any of my other medications, including supplements, interact with nebivolol?
✓How will nebivolol affect my diabetes management or exercise capacity?
✓When and how should I taper if we eventually decide to stop it?

Schedule an Appointment

Related Health Conditions

This medication is commonly used to treat or manage the following conditions:

Portal Hypertension

Portal hypertension, an elevated pressure in the portal vein due to blockage often from cirrhosis or other pre-hepatic causes, can lead to serious complications like bleeding and ascites.

Learn More

Secondary Pulmonary Hypertension

Secondary pulmonary hypertension, unlike its primary form, arises from underlying conditions such as heart/lung disease, blood clots, or connective tissue disorders, increasing lung artery pressure.

Learn More

Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.